LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 13 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 3. - Dataset (ID:20250)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | CP724714 | 0.12 | uM | LJP5 | 72 | hr | 1401 | 2814 | 4245 | 0.6638 | 0.5469 |
| SK-BR-3 | CP724714 | 3.33 | uM | LJP5 | 72 | hr | 1401 | 1856 | 4245 | 0.4371 | 0.1900 |
| SK-BR-3 | CP724714 | 10 | uM | LJP5 | 72 | hr | 1401 | 1398 | 4245 | 0.3282 | -0.0075 |
| SK-BR-3 | Alvocidib | 0.12 | uM | LJP6 | 72 | hr | 1401 | 964 | 4168 | 0.2315 | -0.2115 |
| SK-BR-3 | Alvocidib | 0.37 | uM | LJP6 | 72 | hr | 1401 | 959 | 4168 | 0.2302 | -0.2145 |
| SK-BR-3 | Seliciclib | 0.04 | uM | LJP5 | 72 | hr | 1401 | 4169 | 4245 | 0.9826 | 0.9786 |
| SK-BR-3 | Seliciclib | 0.12 | uM | LJP5 | 72 | hr | 1401 | 4234 | 4245 | 0.9990 | 1.0004 |
| SK-BR-3 | Seliciclib | 1.11 | uM | LJP5 | 72 | hr | 1401 | 3763 | 4245 | 0.8864 | 0.8542 |
| SK-BR-3 | Seliciclib | 3.33 | uM | LJP5 | 72 | hr | 1401 | 3235 | 4245 | 0.7609 | 0.6836 |
| SK-BR-3 | AT-7519 | 0.12 | uM | LJP6 | 72 | hr | 1401 | 1469 | 4168 | 0.3528 | 0.0307 |
| SK-BR-3 | AT-7519 | 0.37 | uM | LJP6 | 72 | hr | 1401 | 1174 | 4168 | 0.2819 | -0.1064 |
| SK-BR-3 | AT-7519 | 3.33 | uM | LJP6 | 72 | hr | 1401 | 711 | 4168 | 0.1708 | -0.3524 |
| SK-BR-3 | AT-7519 | 10 | uM | LJP6 | 72 | hr | 1401 | 486 | 4168 | 0.1167 | -0.4930 |
| SK-BR-3 | AZD7762 | 1.11 | uM | LJP6 | 72 | hr | 1401 | 1112 | 4168 | 0.2665 | -0.1380 |
| SK-BR-3 | AZD7762 | 3.33 | uM | LJP6 | 72 | hr | 1401 | 1020 | 4168 | 0.2452 | -0.1849 |
| SK-BR-3 | AZD8055 | 0.04 | uM | LJP6 | 72 | hr | 1401 | 1460 | 4168 | 0.3504 | 0.0264 |
| SK-BR-3 | AZD8055 | 0.12 | uM | LJP6 | 72 | hr | 1401 | 1438 | 4168 | 0.3455 | 0.0170 |
| SK-BR-3 | AZD8055 | 3.33 | uM | LJP6 | 72 | hr | 1401 | 1289 | 4168 | 0.3097 | -0.0518 |
| SK-BR-3 | AZD8055 | 10 | uM | LJP6 | 72 | hr | 1401 | 443 | 4168 | 0.1063 | -0.5192 |
| SK-BR-3 | Sorafenib | 0.12 | uM | LJP6 | 72 | hr | 1401 | 4043 | 4168 | 0.9705 | 0.9625 |
| SK-BR-3 | Sorafenib | 0.37 | uM | LJP6 | 72 | hr | 1401 | 4190 | 4168 | 1.0057 | 1.0077 |
| SK-BR-3 | CP466722 | 0.12 | uM | LJP5 | 72 | hr | 1401 | 4299 | 4245 | 1.0206 | 1.0288 |
| SK-BR-3 | CP466722 | 0.37 | uM | LJP5 | 72 | hr | 1401 | 4613 | 4245 | 1.0928 | 1.1181 |
| SK-BR-3 | GW843682X | 0.12 | uM | LJP6 | 72 | hr | 1401 | 2267 | 4168 | 0.5435 | 0.3565 |
| SK-BR-3 | GW843682X | 0.04 | uM | LJP6 | 72 | hr | 1401 | 3654 | 4168 | 0.8765 | 0.8390 |